Pharmacokinetic and pharmacodynamic requirements for antibiotic therapy of experimental endocarditis
about
Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis.Investigation of antimicrobial use at a tertiary care hospital in Southern Punjab, Pakistan using WHO methodology.In vivo bactericidal activities of ciprofloxacin and pefloxacin in an experimental model of Serratia marcescens endocarditis.Minocycline versus vancomycin for treatment of experimental endocarditis caused by oxacillin-resistant Staphylococcus aureusBactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis.Different aminoglycoside-resistant phenotypes in a rabbit Staphylococcus aureus endocarditis infection modelEfficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococciDead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance.Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot model.Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots.The population dynamics of antimicrobial chemotherapy.Adaptive resistance of Pseudomonas aeruginosa induced by aminoglycosides and killing kinetics in a rabbit endocarditis modelPharmacodynamics of RP 59500 (quinupristin-dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.Comparison of six generic vancomycin products for treatment of methicillin-resistant Staphylococcus aureus experimental endocarditis in rabbits.WHO/INRUD prescribing indicators and prescribing trends of antibiotics in the Accident and Emergency Department of Bahawal Victoria Hospital, Pakistan.A closer look at vancomycin, teicoplanin, and antimicrobial resistance.Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin.Endocarditis due to Yersinia enterocolitica.Outpatient parenteral antimicrobial therapy in Enterococcus faecalis infective endocarditis.Guidelines for the antibiotic treatment of endocarditis in adults: report of the Working Party of the British Society for Antimicrobial Chemotherapy.
P2860
Q33594066-D25D8B3F-74AB-4106-9768-90294EB9013EQ33617774-39D4BE87-547D-4199-A05E-54305013CF3FQ33753649-C9BB9E18-A263-4358-8258-60FB717D3C15Q33754412-0F3FCF55-194A-43CE-B2F4-51B117BE9601Q33758399-779479C0-ECB5-492F-8569-99AE3AD33F95Q34106959-37699021-F85A-4727-BAB8-766AF6B53F5CQ35005511-62C59D44-132F-45D8-B3E4-DFC6FD3749AFQ35047705-4A4A98EB-851E-4127-A140-522761A20A94Q35116133-0F643CD6-5E6F-426A-98F1-F1AA9917F905Q35123155-404A72D6-91CA-4BE9-AA3F-B2871AF8E86AQ35132378-821806A1-EB36-49F5-8607-31524EC27227Q35135145-D580E774-D922-4135-A89C-AFE525C38131Q35136776-F14DFD49-0DBD-4354-ADC3-84271B5072D4Q36083619-699C75BC-6C0C-48F3-B0F3-C62CD9E6AB53Q36667020-E1ED6EDB-95B5-4548-8E2B-6EE2FAB44478Q37399162-0D03D80E-11E0-42EA-A079-966F539350C2Q41646436-584E4A00-9C13-4DAA-89FC-C24D74913545Q43453462-5EE4E9CE-86B7-4511-AAFB-3D4C06819CE9Q44648940-B868D9FA-413E-4AA4-BD0F-50CE65F3BB7CQ47654438-1972E961-0141-4194-9AFE-86C749FC17DBQ53879693-48B343AF-8AAC-41AA-A761-507350D94C06
P2860
Pharmacokinetic and pharmacodynamic requirements for antibiotic therapy of experimental endocarditis
description
1992 nî lūn-bûn
@nan
1992 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Pharmacokinetic and pharmacody ...... y of experimental endocarditis
@ast
Pharmacokinetic and pharmacody ...... y of experimental endocarditis
@en
type
label
Pharmacokinetic and pharmacody ...... y of experimental endocarditis
@ast
Pharmacokinetic and pharmacody ...... y of experimental endocarditis
@en
prefLabel
Pharmacokinetic and pharmacody ...... y of experimental endocarditis
@ast
Pharmacokinetic and pharmacody ...... y of experimental endocarditis
@en
P2860
P356
P1476
Pharmacokinetic and pharmacody ...... y of experimental endocarditis
@en
P2093
P2860
P304
P356
10.1128/AAC.36.10.2069
P407
P577
1992-10-01T00:00:00Z